Dabigatran, a direct thrombin inhibitor and 2 factor Xa inhibitors, rivaroxaban and apixaban,
are target‑‑specific oral anticoagulants (TSOACs) approved for prevention of stroke or …

Increasing use of the new oral anticoagulants (NOACs)–dabigatran, rivaroxaban, and
apixaban–has prompted considerable discussion in the medical community even as …

The aim of our article is to provide a concise review for clinicians entailing the main studies
that evaluated the efficacy and safety of target-specific oral anticoagulants (TSOAs) for …

Novel oral anticoagulants, including dabigatran, rivaroxaban, and apixaban, represent new
options for preventing stroke in patients with atrial fibrillation, as shown by the results from …

Atrial fibrillation (AF) is a common heart rhythm disturbance; its incidence increases with
age, and it is also an independent risk factor for stroke. Anticoagulation has been proven as …

Atrial fibrillation (AF) confers a significant risk of stroke or systemic thromboembolism. Oral
anticoagulation is the most effective therapy for AF-related stroke prevention. A decision to …

Background—Dabigatran, an oral thrombin inhibitor, and rivaroxaban and apixaban, oral
factor Xa inhibitors, have been found to be safe and effective in reducing stroke risk in …

For more than 60 years, vitamin K antagonists have been the only available oral
anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation (AF) …

In this overview we address the three phase III studies that compared new oral
anticoagulants (dabigatran, rivaroxaban and apixaban) with warfarin in the setting of stroke …

The presence of atrial fibrillation (AF), the most common sustained cardiac arrhythmia,
significantly increases the risk for stroke. Current guidelines recommend that the vitamin K …